Fotemustine

Fotemustine

Systematic (IUPAC) name
(RS)-diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino} ethyl)phosphonate
Clinical data
AHFS/Drugs.com	International Drug Names
Identifiers
CAS Number	92118-27-9
ATC code	L01AD05 (WHO)
PubChem	CID 104799
DrugBank	DB04106
ChemSpider	94600
UNII	GQ7JL9P5I2
KEGG	D07255
ChEMBL	CHEMBL549386
Chemical data
Formula	C9H19ClN3O5P
Molar mass	315.691 g/mol
SMILES O=P(OCC)(OCC)C(NC(=O)N(N=O)CCCl)C
InChI InChI=1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14) Key:YAKWPXVTIGTRJH-UHFFFAOYSA-N
(what is this?)  (verify)

Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study^[1] has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).

External links

1. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M (March 2004). "Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study" 22 (6): 1118–25. doi:10.1200/JCO.2004.04.165. PMID 15020614.